Trial Profile
A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors BerGenBio
- 06 Nov 2023 According to a BerGenBio media release, data from the study were presented at the 2023 Society of Immunotherapy of Cancer Annual Meeting.
- 31 Oct 2023 According to a BerGenBio media release, the full poster from this study will be available on BerGenBio's website shortly following presentation on November 4th.
- 31 Oct 2023 According to a BerGenBio media release, the poster abstract from this study published in the Journal for Immunotherapy of Cancer (JITC).